Reata Pharmaceuticals Fourth Quarter Financial Results and Update on Development Programs

INITIATED ROLLING SUBMISSION OF NDA FOR OMAVELOXOLONE FOR TREATMENT OF PATIENTS WITH FRIEDREICH’S ATAXIA; ACTIVELY PREPARING FOR COMMERCIAL LAUNCH

UPDATED CASH GUIDANCE - SUFFICIENT TO FUND OPERATIONS THROUGH END OF 2024

CONFERENCE CALL WITH MANAGEMENT ON FEBRUARY 28, 2022, AT 8:30 A.M. ET

PLANO, Texas—February 28, 2022 (BUSINESS WIRE)—Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the quarter and full year ended on December 31, 2021 and provided an update on the Company’s business operations and clinical development programs.

"We are making important progress in our efforts to advance omaveloxolone for the treatment of patients with Friedreich’s ataxia (“FA”) including receiving Fast Track Designation from the U.S. Food and Drug Administration (“FDA”) and initiating rolling submission of our New Drug Application (“NDA”). As we continue to complete the submission of our NDA for omaveloxolone, we are also actively preparing for the commercial launch of the drug early next year,” said Warren Huff, Reata’s Chief Executive Officer. “Our strong balance sheet has permitted us to continue the development of drugs for deadly diseases with few or no available therapies. We look forward to providing additional updates as we advance towards key milestones."

Read the Full article here